| Zeinab Houjaij, OD | |
|
22320 Goddard Rd, Taylor, MI 48180-4234 | |
| (313) 299-8870 | |
| (313) 299-8872 |
| Full Name | Zeinab Houjaij |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | 22320 Goddard Rd, Taylor, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477122976 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 4901005513 (Michigan) | Primary |
| Provider Name | Eye Institute Of South Eastern Michigan |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1831304765 PECOS PAC ID: 6204727738 Enrollment ID: O20040323001258 |
News Archive
A genetic analysis reported in Nature suggests two mechanisms that could lead to bipolar disorder.
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market sevelamer carbonate for oral suspension, 0.8g and 2.4g per packet. Watson's sevelamer carbonate for oral suspension product is the generic version of Genzyme's Renvela for Oral Suspension.
The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.
A common first-line treatment approach for cryptococcal meningitis in low-income countries is being compromised by the emergence of drug resistance, new University of Liverpool research warns.
› Verified 2 days ago
| Provider Name | Visionworks Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1366822991 PECOS PAC ID: 4385639616 Enrollment ID: O20151002002485 |
News Archive
A genetic analysis reported in Nature suggests two mechanisms that could lead to bipolar disorder.
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market sevelamer carbonate for oral suspension, 0.8g and 2.4g per packet. Watson's sevelamer carbonate for oral suspension product is the generic version of Genzyme's Renvela for Oral Suspension.
The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.
A common first-line treatment approach for cryptococcal meningitis in low-income countries is being compromised by the emergence of drug resistance, new University of Liverpool research warns.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Zeinab Houjaij, OD 118 Cass Ave, Mount Clemens, MI 48043-2204 Ph: (586) 468-7370 | Zeinab Houjaij, OD 22320 Goddard Rd, Taylor, MI 48180-4234 Ph: (313) 299-8870 |
News Archive
A genetic analysis reported in Nature suggests two mechanisms that could lead to bipolar disorder.
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market sevelamer carbonate for oral suspension, 0.8g and 2.4g per packet. Watson's sevelamer carbonate for oral suspension product is the generic version of Genzyme's Renvela for Oral Suspension.
The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.
A common first-line treatment approach for cryptococcal meningitis in low-income countries is being compromised by the emergence of drug resistance, new University of Liverpool research warns.
› Verified 2 days ago
Trang Nguyen, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 22320 Goddard Rd, Taylor, MI 48180 Phone: 313-299-8872 | |
Dr. Sara Rose Direzze, OD Optometrist Medicare: Medicare Enrolled Practice Location: 22395 Eureka Rd, Taylor, MI 48180 Phone: 734-324-0996 | |
Dr. John Tyler Parmer, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 22395 Eureka Rd, Taylor, MI 48180 Phone: 734-324-0996 | |
Dr. Melissa Dattilo, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 23000 Eureka Rd, Taylor, MI 48180 Phone: 734-374-8500 Fax: 734-374-0957 | |
Dr. Frank Donald Kozin, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 8212 Telegraph Rd, Taylor, MI 48180 Phone: 313-291-7450 | |
Dr. Dina Akhdar-baghdadi, OD Optometrist Medicare: Medicare Enrolled Practice Location: 22395 Eureka Rd, Taylor, MI 48180 Phone: 734-324-0996 | |
Dr. Mohamed M Moussa, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 23000 Eureka Rd, Taylor, MI 48180 Phone: 734-374-8500 Fax: 734-374-0957 |